Irinotecan-Based Regimens for the Second-Line Treatment of Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas: A Monocentric Experience

被引：0
|
作者：
Bardasi, C. [1 ]
Caputo, F. [1 ]
Santini, C. [1 ]
Cerma, K. [1 ]
Gardini, Casadei A. [1 ]
Andrikou, K. [1 ]
Salati, M. [1 ]
Fontana, A. [1 ]
Spallanzani, A. [1 ]
Bertolini, F. [1 ]
Luppi, G. [1 ]
Gelsomino, F. [1 ]
机构：
[1] Univ Hosp Modena, Dept Oncol & Hematol, Modena, Italy
来源：
NEUROENDOCRINOLOGY | 2020年 / 110卷
关键词：
neuroendocrine carcinoma; irinotecan; survival; second line treatment; nec; chemotherapy;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
H03
引用
收藏
页码：180 / 180
页数：1
相关论文
共 50 条
  • [21] Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy
    Shitara, Kohei
    Yuki, Satoshi
    Yamazaki, Kentaro
    Naito, Yoichi
    Fukushima, Hiraku
    Komatsu, Yoshito
    Yasui, Hirofumi
    Takano, Toshimi
    Muro, Kei
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (04) : 595 - 603
  • [22] VALIDATION STUDY OF A PROGNOSTIC CLASSIFICATION SYSTEM IN PATIENTS WITH METASTATIC COLORECTAL CANCER WHO RECEIVED IRINOTECAN-BASED SECOND-LINE CHEMOTHERAPY
    Naito, Y.
    Shitara, K.
    Yamazaki, K.
    Yuki, S.
    Yasui, H.
    Kawamoto, Y.
    Takano, T.
    Komatsu, Y.
    Muro, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 87 - 87
  • [23] Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part A (pembrolizumab alone).
    Mulvey, Claire
    Raj, Nitya Prabhakar
    Chan, Jennifer A.
    Aggarwal, Rahul Raj
    Cinar, Pelin
    Hope, Thomas A.
    Kolli, Kanti
    Zhang, Li
    Calabrese, Susan
    Grabowsky, Jennifer Ann
    Modarresi, Lila
    Kelly, Virginia
    Stonely, Danielle
    Munster, Pamela N.
    Reidy, Diane Lauren
    Fong, Lawrence
    Bergsland, Emily K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [24] Validation study of a prognostic classification system in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy.
    Yamazaki, Kentaro
    Naito, Yoichi
    Yuki, Satoshi
    Kawamoto, Yasuyuki
    Yasui, Hirofumi
    Takano, Toshimi
    Komatsu, Yoshito
    Muro, Kei
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [25] Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following failure of fluoropyrimidine-based regimens
    Oba, Masaru
    Chin, Keisho
    Kawazoe, Yoshimasa
    Takagi, Koichi
    Ogura, Mariko
    Shinozaki, Eiji
    Suenaga, Mitsukuni
    Matsusaka, Satoshi
    Mizunuma, Nobuyuki
    Hatake, Kiyohiko
    ONCOLOGY LETTERS, 2011, 2 (02) : 241 - 245
  • [26] Second-Line Treatment in Patients (pts) with Advanced Extra-Pulmonary Poorly Differentiated Neuroendocrine Carcinoma (EP-PD-NEC): A Systematic Review and Meta-Analysis
    McNamara, M. G.
    Frizziero, M.
    Jacobs, T.
    Lamarca, A.
    Hubner, R.
    Valle, J. W.
    Amir, E.
    NEUROENDOCRINOLOGY, 2019, 108 : 188 - 188
  • [27] Immunotherapy as Second-line Treatment in Grade 3 Neuroendocrine Carcinomas: A Prospective Case Series from an ENETS Center of Excellence
    Vandamme, T.
    De Backer, L.
    Van den Brande, J.
    Op de Beeck, B.
    Driessen, A.
    Simoens, M.
    Demey, W.
    Prenen, H.
    Peeters, M.
    Lybaert, W.
    NEUROENDOCRINOLOGY, 2020, 110 : 219 - 219
  • [28] Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part B (pembrolizumab plus chemotherapy).
    Chan, Jennifer A.
    Raj, Nitya Prabhakar
    Aggarwal, Rahul Raj
    Calabrese, Susan
    DeMore, April
    Dhawan, Mallika Sachdev
    Fattah, Delaire
    Fong, Lawrence
    Grabowsky, Jennifer
    Hope, Thomas A.
    Kolli, Kanti Pallav
    Munster, Pamela N.
    Perez, Kimberly
    Reidy, Diane Lauren
    Von Fedak, Sofia
    Zhang, Li
    Bergsland, Emily K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy
    Kakolyris, S.
    Souglakos, J.
    Polyzos, A.
    Ardavanis, A.
    Ziras, N.
    Athanasiadis, A.
    Varthalitis, I.
    Amarantidis, K.
    Tsousis, S.
    Vamvakas, L.
    Vardakis, N.
    Georgoulias, V.
    ONCOLOGY, 2008, 74 (1-2) : 31 - 36
  • [30] Survival of second-line irinotecan-based chemotherapy in early relapse patients with gastric cancer after adjuvant chemotherapy: Exploratory subgroup analysis of TRICS trial
    Nishikawa, Kazuhiro
    Murotani, Kenta
    Fujitani, Kazumasa
    Inagaki, Hiroshi
    Akamaru, Yuske
    Tokunaga, Shinya
    Takagi, Masakazu
    Tamura, Shigeyuki
    Sugimoto, Naotoshi
    Shigematsu, Tadashi
    Yoshikawa, Takaki
    Ishiguro, Tohru
    Nakamura, Masato
    Miyashita, Yumi
    Morita, Satoshi
    Tsuburaya, Akira
    Sakamoto, Junichi
    Tsujinaka, Toshimasa
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345